Transaction support: Case Studies

Pharma, Healthcare and Biotech

Case study 1: Technical and commercial due diligence on a company developing gene and cell-based therapeutics

We prepared an independent report to support the fundraising plans of a European company developing gene and cell-based therapies for cancer and AIDS. In a structured process we analysed the preclinical and clinical data supporting the company’s products, the commercial potential, the barriers to adoption, and the feasibility and risks of the business plan.

Our report reviewed the portfolio of products in clinical development and highlighted key issues with the company’s plans The Company raised a further round of private financing.

Engineering

Case study 2: Commercial due diligence of COTS FPGA computing board

We undertook a commercial due diligence of a European semi-conductor company on behalf of a UK investor. We assessed the market potential and competitive environment for each of the company’s key products and production capability. We also visited and assessed the company site and manufacturing facilities. We presented a clear picture of the merits of the company’s products, market potential and risk management. We highlighted supplier issues that represented both risks and opportunities for the right investor. Our client was able to base their investment decision on a clear view of the business potential.

Cleantech

Case study 3: Expert Report to support the submission of TyraTech to the London Stock Exchange.

Our client TyraTech Inc. required an Expert Report to support their admission to the London Stock Exchange. TyraTech is developing and commercializing a new class of highly effective, non-toxic pesticides using cloned insect chemoreceptors, based on approved, safe, natural oils to kill or repel insects and parasites.

In preparing the report we examined many aspects of TyraTech’s technologies, products, pipeline opportunities, manufacturing and commercial partnerships, as well as capabilities of the Management Team. Key was a screening platform which pesticide blends can be rationally designed, screened and repeatedly re-blended to maximise the efficacy and optimise the response against an invertebrate.

As a result of our study the investors were able to gain an independent view on the technical and commercial aspects of the business including the risks in the agricultural and food. TyraTech successfully listed raising £25m.